This federal contract award, valued at $12,654.42, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a medication for diabetes management. The contract has an ultimate completion date of November 7, 2024, and is a firm-fixed-price arrangement.
AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.
This contract award does not have a set-aside designation, indicating open competition. The DLA is a defense agency responsible for providing logistics, acquisition, and technical services to the U.S. military, other federal agencies, and partner nations. The DLA's Troop Support Medical division specializes in the procurement and distribution of pharmaceutical and medical products for military treatment facilities, veterans' healthcare programs, and other federal medical institutions.
Generated 2/5/25, 9:29 AM